{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T21:57:33Z","timestamp":1791496653632,"version":"4.3.4"},"reference-count":82,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,10,11]]},"DOI":"10.7759\/cureus.30195","type":"journal-article","created":{"date-parts":[[2022,10,12]],"date-time":"2022-10-12T00:19:47Z","timestamp":1665533987000},"source":"Crossref","is-referenced-by-count":5,"title":["The Association Between Alzheimer's Disease and Epilepsy: A Narrative Review"],"prefix":"10.7759","author":[{"given":"Manisha","family":"Purushotham","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatema","family":"Tashrifwala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rahul","family":"Jena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunil Akshara","family":"Vudugula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rutuja S","family":"Patil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aditi","family":"Agrawal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","unstructured":"World Alzheimer Report. (2015). http.\/\/www.alz.co.uk\/research\/statistics."},{"key":"ref2","unstructured":"Dementia. (2022). https.\/\/www.who.int\/news-room\/fact-sheets\/detail\/dementia."},{"key":"ref3","unstructured":"World Alzheimer Report 2021. (2021). https.\/\/www.alzint.org\/resource\/world-alzheimer-report-2021\/."},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(17)30044-3","article-title":"Epileptic activity in Alzheimer's disease: causes and clinical relevance","volume":"16","author":"Vossel KA","year":"2017","unstructured":"Vossel KA, Tartaglia MC, Nygaard HB, Zeman AZ, Miller BL. Epileptic activity in Alzheimer's disease: causes and clinical relevance. Lancet Neurol. 2017, 16:311-22. 10.1016\/S1474-4422(17)30044-3","journal-title":"Lancet Neurol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1002\/ana.24794","article-title":"Incidence and impact of subclinical epileptiform activity in Alzheimer's disease","volume":"80","author":"Vossel KA","year":"2016","unstructured":"Vossel KA, Ranasinghe KG, Beagle AJ, et al.. Incidence and impact of subclinical epileptiform activity in Alzheimer's disease. Ann Neurol. 2016, 80:858-70. 10.1002\/ana.24794","journal-title":"Ann Neurol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1001\/archneurol.2009.130","article-title":"Seizures in Alzheimer disease: who, when, and how common?","volume":"66","author":"Scarmeas N","year":"2009","unstructured":"Scarmeas N, Honig LS, Choi H, et al.. Seizures in Alzheimer disease: who, when, and how common?. Arch Neurol. 2009, 66:992-7. 10.1001\/archneurol.2009.130","journal-title":"Arch Neurol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.36.9.1226","article-title":"Seizures and myoclonus in patients with Alzheimer's disease","volume":"36","author":"Hauser WA","year":"1986","unstructured":"Hauser WA, Morris ML, Heston LL, Anderson VE. Seizures and myoclonus in patients with Alzheimer's disease. Neurology. 1986, 36:1226-30. 10.1212\/wnl.36.9.1226","journal-title":"Neurology"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000010358","article-title":"A nationwide, retrospective, data-linkage, cohort study of epilepsy and incident dementia","volume":"95","author":"Schnier C","year":"2020","unstructured":"Schnier C, Duncan S, Wilkinson T, Mbizvo GK, Chin RF. A nationwide, retrospective, data-linkage, cohort study of epilepsy and incident dementia. Neurology. 2020, 95:e1686-93. 10.1212\/WNL.0000000000010358","journal-title":"Neurology"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1038\/nn.3376","article-title":"Spike bursts increase amyloid-\u03b2 40\/42 ratio by inducing a presenilin-1 conformational change","volume":"16","author":"Dolev I","year":"2013","unstructured":"Dolev I, Fogel H, Milshtein H, et al.. Spike bursts increase amyloid-\u03b2 40\/42 ratio by inducing a presenilin-1 conformational change. Nat Neurosci. 2013, 16:587-95. 10.1038\/nn.3376","journal-title":"Nat Neurosci"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2006.00554.x","article-title":"Incidence and predictors of seizures in patients with Alzheimer's disease","volume":"47","author":"Amatniek JC","year":"2006","unstructured":"Amatniek JC, Hauser WA, DelCastillo-Castaneda C, et al.. Incidence and predictors of seizures in patients with Alzheimer's disease. Epilepsia. 2006, 47:867-72. 10.1111\/j.1528-1167.2006.00554.x","journal-title":"Epilepsia"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.2165\/00002512-200320110-00001","article-title":"Seizures in elderly patients with dementia: epidemiology and management","volume":"20","author":"Mendez M","year":"2003","unstructured":"Mendez M, Lim G. Seizures in elderly patients with dementia: epidemiology and management. Drugs Aging. 2003, 20:791-803. 10.2165\/00002512-200320110-00001","journal-title":"Drugs Aging"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2013.136","article-title":"Seizures and epileptiform activity in the early stages of Alzheimer disease","volume":"70","author":"Vossel KA","year":"2013","unstructured":"Vossel KA, Beagle AJ, Rabinovici GD, et al.. Seizures and epileptiform activity in the early stages of Alzheimer disease. JAMA Neurol. 2013, 70:1158-66. 10.1001\/jamaneurol.2013.136","journal-title":"JAMA Neurol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.nicl.2015.02.009","article-title":"Response of the medial temporal lobe network in amnestic mild cognitive impairment to therapeutic intervention assessed by fMRI and memory task performance","volume":"7","author":"Bakker A","year":"2015","unstructured":"Bakker A, Albert MS, Krauss G, Speck CL, Gallagher M. Response of the medial temporal lobe network in amnestic mild cognitive impairment to therapeutic intervention assessed by fMRI and memory task performance. Neuroimage Clin. 2015, 7:688-98. 10.1016\/j.nicl.2015.02.009","journal-title":"Neuroimage Clin"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1038\/s41582-021-00505-9","article-title":"Amyloid-\u03b2: a potential link between epilepsy and cognitive decline","volume":"17","author":"Romoli M","year":"2021","unstructured":"Romoli M, Sen A, Parnetti L, Calabresi P, Costa C. Amyloid-\u03b2: a potential link between epilepsy and cognitive decline. Nat Rev Neurol. 2021, 17:469-85. 10.1038\/s41582-021-00505-9","journal-title":"Nat Rev Neurol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.redox.2017.10.014","article-title":"Oxidative stress and the amyloid beta peptide in Alzheimer's disease","volume":"14","author":"Cheignon C","year":"2018","unstructured":"Cheignon C, Tomas M, Bonnefont-Rousselot D, Faller P, Hureau C, Collin F. Oxidative stress and the amyloid beta peptide in Alzheimer's disease. Redox Biol. 2018, 14:450-64. 10.1016\/j.redox.2017.10.014","journal-title":"Redox Biol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.brainresbull.2020.04.009","article-title":"Epilepsy and Alzheimer's disease: potential mechanisms for an association","volume":"160","author":"Giorgi FS","year":"2020","unstructured":"Giorgi FS, Saccaro LF, Busceti CL, Biagioni F, Fornai F. Epilepsy and Alzheimer's disease: potential mechanisms for an association. Brain Res Bull. 2020, 160:107-20. 10.1016\/j.brainresbull.2020.04.009","journal-title":"Brain Res Bull"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1186\/s43141-021-00224-0","article-title":"GABAA receptors: structure, function, pharmacology, and related disorders","volume":"19","author":"Ghit A","year":"2021","unstructured":"Ghit A, Assal D, Al-Shami AS, Hussein DE. GABAA receptors: structure, function, pharmacology, and related disorders. J Genet Eng Biotechnol. 2021, 19:123. 10.1186\/s43141-021-00224-0","journal-title":"J Genet Eng Biotechnol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuint.2004.03.007","article-title":"Glutamate-mediated excitotoxicity and neurodegeneration in Alzheimer's disease","volume":"45","author":"Hynd MR","year":"2004","unstructured":"Hynd MR, Scott HL, Dodd PR. Glutamate-mediated excitotoxicity and neurodegeneration in Alzheimer's disease. Neurochem Int. 2004, 45:583-95. 10.1016\/j.neuint.2004.03.007","journal-title":"Neurochem Int"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21103676","article-title":"Unravelling the role of glycogen synthase kinase-3 in Alzheimer\u2019s disease-related epileptic seizures","volume":"21","author":"Lin R","year":"2020","unstructured":"Lin R, Jones NC, Kwan P. Unravelling the role of glycogen synthase kinase-3 in Alzheimer\u2019s disease-related epileptic seizures. Int J Mol Sci. 2020, 21:10.3390\/ijms21103676","journal-title":"Int J Mol Sci"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000011080","article-title":"Dementia in late-onset epilepsy: The Atherosclerosis Risk in Communities study","volume":"95","author":"Johnson EL","year":"2020","unstructured":"Johnson EL, Krauss GL, Kucharska-Newton A, et al.. Dementia in late-onset epilepsy: The Atherosclerosis Risk in Communities study. Neurology. 2020, 95:e3248-56. 10.1212\/WNL.0000000000011080","journal-title":"Neurology"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.2174\/1567205014666170417111859","article-title":"Tau in Alzheimer's disease: mechanisms and therapeutic strategies","volume":"15","author":"Gao Y","year":"2018","unstructured":"Gao Y, Tan L, Yu JT, Tan L. Tau in Alzheimer's disease: mechanisms and therapeutic strategies. Curr Alzheimer Res. 2018, 15:283-300. 10.2174\/1567205014666170417111859","journal-title":"Curr Alzheimer Res"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.3389\/fncel.2020.00019","article-title":"GSK3\u03b2 and tau protein in Alzheimer's disease and epilepsy","volume":"14","author":"Toral-Rios D","year":"2020","unstructured":"Toral-Rios D, Pichardo-Rojas PS, Alonso-Vanegas M, Campos-Pe\u00f1a V. GSK3\u03b2 and tau protein in Alzheimer's disease and epilepsy. Front Cell Neurosci. 2020, 14:19. 10.3389\/fncel.2020.00019","journal-title":"Front Cell Neurosci"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/492524","article-title":"Influence of sleep and sleep deprivation on ictal and interictal epileptiform activity","volume":"2013","author":"D\u00edaz-Negrillo A","year":"2013","unstructured":"D\u00edaz-Negrillo A. Influence of sleep and sleep deprivation on ictal and interictal epileptiform activity. Epilepsy Res Treat. 2013, 2013:492524. 10.1155\/2013\/492524","journal-title":"Epilepsy Res Treat"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-160994","article-title":"Sleep EEG detects epileptiform activity in Alzheimer\u2019s disease with high sensitivity","volume":"56","author":"Horv\u00e1th A","year":"2017","unstructured":"Horv\u00e1th A, Sz\u0171cs A, Barcs G, Kamondi A. Sleep EEG detects epileptiform activity in Alzheimer\u2019s disease with high sensitivity. J Alzheimers Dis. 2017, 56:1175-83. 10.3233\/JAD-160994","journal-title":"J Alzheimers Dis"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2021.623777","article-title":"CSF in epileptic prodromal Alzheimer's disease: no diagnostic contribution but a pathophysiological one","volume":"12","author":"Cretin B","year":"2021","unstructured":"Cretin B, Bousiges O, Hautecloque G, et al.. CSF in epileptic prodromal Alzheimer's disease: no diagnostic contribution but a pathophysiological one. Front Neurol. 2021, 12:623777. 10.3389\/fneur.2021.623777","journal-title":"Front Neurol"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1017\/s0317167100013949","article-title":"Early-onset familial Alzheimer's disease (EOFAD)","volume":"39","author":"Wu L","year":"2012","unstructured":"Wu L, Rosa-Neto P, Hsiung GY, et al.. Early-onset familial Alzheimer's disease (EOFAD). Can J Neurol Sci. 2012, 39:436-45. 10.1017\/s0317167100013949","journal-title":"Can J Neurol Sci"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1002\/humu.22117","article-title":"Locus-specific mutation databases for neurodegenerative brain diseases","volume":"33","author":"Cruts M","year":"2012","unstructured":"Cruts M, Theuns J, Van Broeckhoven C. Locus-specific mutation databases for neurodegenerative brain diseases. Hum Mutat. 2012, 33:1340-4. 10.1002\/humu.22117","journal-title":"Hum Mutat"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21239318","article-title":"Modulation of brain hyperexcitability: potential new therapeutic approaches in Alzheimer's disease","volume":"21","author":"Toniolo S","year":"2020","unstructured":"Toniolo S, Sen A, Husain M. Modulation of brain hyperexcitability: potential new therapeutic approaches in Alzheimer's disease. Int J Mol Sci. 2020, 21:10.3390\/ijms21239318","journal-title":"Int J Mol Sci"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1097\/WAD.0000000000000134","article-title":"Epileptic seizures in Alzheimer disease: a review","volume":"30","author":"Horv\u00e1th A","year":"2016","unstructured":"Horv\u00e1th A, Sz\u0171cs A, Barcs G, Noebels JL, Kamondi A. Epileptic seizures in Alzheimer disease: a review. Alzheimer Dis Assoc Disord. 2016, 30:186-92. 10.1097\/WAD.0000000000000134","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1111\/jgs.17101","article-title":"Systematic review of coexistent epileptic seizures and Alzheimer's disease: incidence and prevalence","volume":"69","author":"Xu Y","year":"2021","unstructured":"Xu Y, Lavrencic L, Radford K, et al.. Systematic review of coexistent epileptic seizures and Alzheimer's disease: incidence and prevalence. J Am Geriatr Soc. 2021, 69:2011-20. 10.1111\/jgs.17101","journal-title":"J Am Geriatr Soc"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1111\/jgs.14125","article-title":"Abdominal epilepsy associated with Alzheimer's disease","volume":"64","author":"Hayashida A","year":"2016","unstructured":"Hayashida A, Tomizawa Y, Nakahara T, Furukawa Y. Abdominal epilepsy associated with Alzheimer's disease. J Am Geriatr Soc. 2016, 64:1146-7. 10.1111\/jgs.14125","journal-title":"J Am Geriatr Soc"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.4103\/1673-5374.253519","article-title":"Detrimental and synergistic role of epilepsy - Alzheimer's disease risk factors","volume":"14","author":"Filippov MA","year":"2019","unstructured":"Filippov MA, Vorobyov VV. Detrimental and synergistic role of epilepsy - Alzheimer's disease risk factors. Neural Regen Res. 2019, 14:1376-7. 10.4103\/1673-5374.253519","journal-title":"Neural Regen Res"},{"key":"ref33","article-title":"Depression and apoe\u03b54 status in individuals with subjective cognitive decline: a meta-analysis","author":"Huang YP","year":"2020","unstructured":"Huang YP, Xue JJ, Li C, Chen X, Fu HJ, Fei T, Bi PX. Depression and apoe\u03b54 status in individuals with subjective cognitive decline: a meta-analysis. Psychiatry Investig. 2020, 858-64. https:\/\/www.alzforum.org\/papers\/depression-and-apoee4-status-individuals-subjective-cognitive-decline-meta-analysis","journal-title":"Psychiatry Investig"},{"key":"ref34","article-title":"Alzheimer Disease Overview","author":"Bird TD","year":"2018","unstructured":"Bird TD. Alzheimer Disease Overview. GeneReviews [Internet]. Adam MP, Everman DB, Mirzaa GM, et al. (ed): University of Washington, Seattle; 2018."},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1038\/nrneurol.2017.188","article-title":"Blood-brain barrier breakdown in Alzheimer disease and other neurodegenerative disorders","volume":"14","author":"Sweeney MD","year":"2018","unstructured":"Sweeney MD, Sagare AP, Zlokovic BV. Blood-brain barrier breakdown in Alzheimer disease and other neurodegenerative disorders. Nat Rev Neurol. 2018, 14:133-50. 10.1038\/nrneurol.2017.188","journal-title":"Nat Rev Neurol"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuron.2014.12.032","article-title":"Blood-brain barrier breakdown in the aging human hippocampus","volume":"85","author":"Montagne A","year":"2015","unstructured":"Montagne A, Barnes SR, Sweeney MD, et al.. Blood-brain barrier breakdown in the aging human hippocampus. Neuron. 2015, 85:296-302. 10.1016\/j.neuron.2014.12.032","journal-title":"Neuron"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.12779\/dnd.2018.17.4.156","article-title":"Association of Alzheimer's disease with the risk of developing epilepsy: a 10-Year nationwide cohort study","volume":"17","author":"Lyou HJ","year":"2018","unstructured":"Lyou HJ, Seo KD, Lee JE, Pak HY, Lee JH. Association of Alzheimer's disease with the risk of developing epilepsy: a 10-Year nationwide cohort study. Dement Neurocogn Disord. 2018, 17:156-62. 10.12779\/dnd.2018.17.4.156","journal-title":"Dement Neurocogn Disord"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2022.909669","article-title":"Rodent modeling of Alzheimer's disease in down syndrome: in vivo and ex vivo approaches","volume":"16","author":"Farrell C","year":"2022","unstructured":"Farrell C, Mumford P, Wiseman FK. Rodent modeling of Alzheimer's disease in down syndrome: in vivo and ex vivo approaches. Front Neurosci. 2022, 16:909669. 10.3389\/fnins.2022.909669","journal-title":"Front Neurosci"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.5603\/PJNNS.a2019.0052","article-title":"Antipsychotic drugs in epilepsy","volume":"53","author":"G\u00f3rska N","year":"2019","unstructured":"G\u00f3rska N, S\u0142upski J, Cuba\u0142a WJ. Antipsychotic drugs in epilepsy. Neurol Neurochir Pol. 2019, 53:408-12. 10.5603\/PJNNS.a2019.0052","journal-title":"Neurol Neurochir Pol"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1016\/j.apmr.2013.06.002","article-title":"Information\/education page. Seizures and traumatic brain injury","volume":"95","author":"Englander J","year":"2014","unstructured":"Englander J, Cifu DX, Diaz-Arrastia R. Information\/education page. Seizures and traumatic brain injury. Arch Phys Med Rehabil. 2014, 95:1223-4. 10.1016\/j.apmr.2013.06.002","journal-title":"Arch Phys Med Rehabil"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.5698\/1535-7511-12.5.184","article-title":"Seizures in Alzheimer disease: clinical and epidemiological data","volume":"12","author":"Pandis D","year":"2012","unstructured":"Pandis D, Scarmeas N. Seizures in Alzheimer disease: clinical and epidemiological data. Epilepsy Curr. 2012, 12:184-7. 10.5698\/1535-7511-12.5.184","journal-title":"Epilepsy Curr"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1093\/ageing\/afaa194","article-title":"Neurodegenerative disease is associated with increased incidence of epilepsy: a population based study of older adults","volume":"50","author":"Blank LJ","year":"2021","unstructured":"Blank LJ, Acton EK, Thibault D, Willis AW. Neurodegenerative disease is associated with increased incidence of epilepsy: a population based study of older adults. Age Ageing. 2021, 50:205-12. 10.1093\/ageing\/afaa194","journal-title":"Age Ageing"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2021.637260","article-title":"Predictors of new-onset epilepsy in people with younger-onset neurocognitive disorders","volume":"13","author":"Wang X","year":"2021","unstructured":"Wang X, Loi SM, Foster E, Chen Z, Velakoulis D, Kwan P. Predictors of new-onset epilepsy in people with younger-onset neurocognitive disorders. Front Aging Neurosci. 2021, 13:637260. 10.3389\/fnagi.2021.637260","journal-title":"Front Aging Neurosci"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-170925","article-title":"Prevalence, semiology, and risk factors of epilepsy in Alzheimer's disease: an ambulatory EEG study","volume":"63","author":"Horv\u00e1th A","year":"2018","unstructured":"Horv\u00e1th A, Sz\u0171cs A, Hidasi Z, Csukly G, Barcs G, Kamondi A. Prevalence, semiology, and risk factors of epilepsy in Alzheimer's disease: an ambulatory EEG study. J Alzheimers Dis. 2018, 63:1045-54. 10.3233\/JAD-170925","journal-title":"J Alzheimers Dis"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneumeth.2020.108687","article-title":"On the merits of non-invasive myelin imaging in epilepsy, a literature review","volume":"338","author":"Drenthen GS","year":"2020","unstructured":"Drenthen GS, Backes WH, Aldenkamp AP, Vermeulen RJ, Klinkenberg S, Jansen JF. On the merits of non-invasive myelin imaging in epilepsy, a literature review. J Neurosci Methods. 2020, 338:108687. 10.1016\/j.jneumeth.2020.108687","journal-title":"J Neurosci Methods"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinph.2021.03.050","article-title":"Subclinical epileptiform activity accelerates the progression of Alzheimer's disease: a long-term EEG study","volume":"132","author":"Horvath AA","year":"2021","unstructured":"Horvath AA, Papp A, Zsuffa J, et al.. Subclinical epileptiform activity accelerates the progression of Alzheimer's disease: a long-term EEG study. Clin Neurophysiol. 2021, 132:1982-9. 10.1016\/j.clinph.2021.03.050","journal-title":"Clin Neurophysiol"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000010612","article-title":"Association of epileptiform abnormalities and seizures in Alzheimer disease","volume":"95","author":"Lam AD","year":"2020","unstructured":"Lam AD, Sarkis RA, Pellerin KR, et al.. Association of epileptiform abnormalities and seizures in Alzheimer disease. Neurology. 2020, 95:e2259-70. 10.1212\/WNL.0000000000010612","journal-title":"Neurology"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.3233\/BEN-2009-0227","article-title":"Large-scale functional brain network abnormalities in Alzheimer's disease: insights from functional neuroimaging","volume":"21","author":"Dickerson BC","year":"2009","unstructured":"Dickerson BC, Sperling RA. Large-scale functional brain network abnormalities in Alzheimer's disease: insights from functional neuroimaging. Behav Neurol. 2009, 21:63-75. 10.3233\/BEN-2009-0227","journal-title":"Behav Neurol"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.3389\/fnint.2018.00036","article-title":"Alterations of coherent theta and gamma network oscillations as an early biomarker of temporal lobe epilepsy and Alzheimer's disease","volume":"12","author":"Kitchigina VF","year":"2018","unstructured":"Kitchigina VF. Alterations of coherent theta and gamma network oscillations as an early biomarker of temporal lobe epilepsy and Alzheimer's disease. Front Integr Neurosci. 2018, 12:36. 10.3389\/fnint.2018.00036","journal-title":"Front Integr Neurosci"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1038\/nm.4330","article-title":"Silent hippocampal seizures and spikes identified by foramen ovale electrodes in Alzheimer's disease","volume":"23","author":"Lam AD","year":"2017","unstructured":"Lam AD, Deck G, Goldman A, Eskandar EN, Noebels J, Cole AJ. Silent hippocampal seizures and spikes identified by foramen ovale electrodes in Alzheimer's disease. Nat Med. 2017, 23:678-80. 10.1038\/nm.4330","journal-title":"Nat Med"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.1016\/j.pneurobio.2019.101664","article-title":"microRNA dysregulation in neurodegenerative diseases: a systematic review","volume":"182","author":"Ju\u017awik CA","year":"2019","unstructured":"Ju\u017awik CA, S Drake S, Zhang Y, et al.. microRNA dysregulation in neurodegenerative diseases: a systematic review. Prog Neurobiol. 2019, 182:101664. 10.1016\/j.pneurobio.2019.101664","journal-title":"Prog Neurobiol"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.1016\/j.neulet.2018.07.038","article-title":"PET imaging of synaptic density: a new tool for investigation of neuropsychiatric diseases","volume":"691","author":"Cai Z","year":"2019","unstructured":"Cai Z, Li S, Matuskey D, Nabulsi N, Huang Y. PET imaging of synaptic density: a new tool for investigation of neuropsychiatric diseases. Neurosci Lett. 2019, 691:44-50. 10.1016\/j.neulet.2018.07.038","journal-title":"Neurosci Lett"},{"key":"ref53","article-title":"Brain 18F-FDG-PET: utility in the diagnosis of dementia and epilepsy","volume":"22","author":"Lotan E","year":"2020","unstructured":"Lotan E, Friedman KP, Davidson T, Shepherd TM. Brain 18F-FDG-PET: utility in the diagnosis of dementia and epilepsy. Isr Med Assoc J. 2020, 22:178-84.","journal-title":"Isr Med Assoc J"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.2174\/1568026619666190708163407","article-title":"PET imaging of adenosine receptors in diseases","volume":"19","author":"Li J","year":"2019","unstructured":"Li J, Hong X, Li G, Conti PS, Zhang X, Chen K. PET imaging of adenosine receptors in diseases. Curr Top Med Chem. 2019, 19:1445-63. 10.2174\/1568026619666190708163407","journal-title":"Curr Top Med Chem"},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.1016\/j.neurol.2017.03.028","article-title":"Do we know how to diagnose epilepsy early in Alzheimer's disease?","volume":"173","author":"Cretin B","year":"2017","unstructured":"Cretin B, Philippi N, Bousiges O, Dibitonto L, Sellal F, Martin-Hunyadi C, Blanc F. Do we know how to diagnose epilepsy early in Alzheimer's disease?. Rev Neurol (Paris). 2017, 173:374-80. 10.1016\/j.neurol.2017.03.028","journal-title":"Rev Neurol (Paris)"},{"key":"ref56","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011922.pub4","article-title":"Treatment of epilepsy for people with Alzheimer's disease","volume":"5","author":"Liu J","year":"2021","unstructured":"Liu J, Wang LN. Treatment of epilepsy for people with Alzheimer's disease. Cochrane Database Syst Rev. 2021, 5:CD011922. 10.1002\/14651858.CD011922.pub4","journal-title":"Cochrane Database Syst Rev"},{"key":"ref57","doi-asserted-by":"publisher","DOI":"10.3390\/medicina56070320","article-title":"Pharmacological Interactions in the elderly","volume":"56","author":"B\u0142eszy\u0144ska E","year":"2020","unstructured":"B\u0142eszy\u0144ska E, Wierucki \u0141, Zdrojewski T, Renke M. Pharmacological Interactions in the elderly. Medicina (Kaunas). 2020, 56:10.3390\/medicina56070320","journal-title":"Medicina (Kaunas)"},{"key":"ref58","doi-asserted-by":"publisher","DOI":"10.1590\/S1980-57642014DN81000010","article-title":"Epilepsy in patients with Alzheimer's disease: a systematic review","volume":"8","author":"Miranda DD","year":"2014","unstructured":"Miranda DD, Brucki SM. Epilepsy in patients with Alzheimer's disease: a systematic review. Dement Neuropsychol. 2014, 8:66-71. 10.1590\/S1980-57642014DN81000010","journal-title":"Dement Neuropsychol"},{"key":"ref59","doi-asserted-by":"publisher","DOI":"10.1093\/ajhp\/62.4.0420","article-title":"Seizures associated with memantine use","volume":"62","author":"Peltz G","year":"2005","unstructured":"Peltz G, Pacific DM, Noviasky JA, Shatla A, Mehalic T. Seizures associated with memantine use. Am J Health Syst Pharm. 2005, 62:420-1. 10.1093\/ajhp\/62.4.0420","journal-title":"Am J Health Syst Pharm"},{"key":"ref60","doi-asserted-by":"publisher","DOI":"10.4103\/0972-2327.179971","article-title":"Evaluating the efficacy of memantine on improving cognitive functions in epileptic patients receiving anti-epileptic drugs: a double-blind placebo-controlled clinical trial (Phase IIIb pilot study)","volume":"19","author":"Marimuthu P","year":"2016","unstructured":"Marimuthu P, Varadarajan S, Krishnan M, et al.. Evaluating the efficacy of memantine on improving cognitive functions in epileptic patients receiving anti-epileptic drugs: a double-blind placebo-controlled clinical trial (Phase IIIb pilot study). Ann Indian Acad Neurol. 2016, 19:344-50. 10.4103\/0972-2327.179971","journal-title":"Ann Indian Acad Neurol"},{"key":"ref61","doi-asserted-by":"publisher","DOI":"10.1016\/j.seizure.2009.11.005","article-title":"Seizure risk associated with neuroactive drugs: data from the WHO adverse drug reactions database","volume":"19","author":"Kumlien E","year":"2010","unstructured":"Kumlien E, Lundberg PO. Seizure risk associated with neuroactive drugs: data from the WHO adverse drug reactions database. Seizure. 2010, 19:69-73. 10.1016\/j.seizure.2009.11.005","journal-title":"Seizure"},{"key":"ref62","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2007.01114.x","article-title":"A randomized, double-blind, placebo-controlled trial of donepezil to improve memory in epilepsy","volume":"48","author":"Hamberger MJ","year":"2007","unstructured":"Hamberger MJ, Palmese CA, Scarmeas N, Weintraub D, Choi H, Hirsch LJ. A randomized, double-blind, placebo-controlled trial of donepezil to improve memory in epilepsy. Epilepsia. 2007, 48:1283-91. 10.1111\/j.1528-1167.2007.01114.x","journal-title":"Epilepsia"},{"key":"ref63","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2008.05.006","article-title":"The safety and tolerability of galantamine in patients with epilepsy and memory difficulties","volume":"13","author":"Griffith HR","year":"2008","unstructured":"Griffith HR, Martin R, Andrews S, LeBron Paige A, Ware J, Faught E, Welty T. The safety and tolerability of galantamine in patients with epilepsy and memory difficulties. Epilepsy Behav. 2008, 13:376-80. 10.1016\/j.yebeh.2008.05.006","journal-title":"Epilepsy Behav"},{"key":"ref64","doi-asserted-by":"publisher","DOI":"10.7573\/dic.2021-7-3","article-title":"Aducanumab: evidence from clinical trial data and controversies","volume":"10","author":"Tampi RR","year":"2021","unstructured":"Tampi RR, Forester BP, Agronin M. Aducanumab: evidence from clinical trial data and controversies. Drugs Context. 2021, 10:10.7573\/dic.2021-7-3","journal-title":"Drugs Context"},{"key":"ref65","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-015-0262-y","article-title":"Antipsychotic drug use and the risk of seizures: follow-up study with a nested case-control analysis","volume":"29","author":"Bloechliger M","year":"2015","unstructured":"Bloechliger M, R\u00fcegg S, Jick SS, Meier CR, Bodmer M. Antipsychotic drug use and the risk of seizures: follow-up study with a nested case-control analysis. CNS Drugs. 2015, 29:591-603. 10.1007\/s40263-015-0262-y","journal-title":"CNS Drugs"},{"key":"ref66","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2008.08.012","article-title":"Recurrent seizures in patients with dementia: frequency, seizure types, and treatment outcome","volume":"14","author":"Rao SC","year":"2009","unstructured":"Rao SC, Dove G, Cascino GD, Petersen RC. Recurrent seizures in patients with dementia: frequency, seizure types, and treatment outcome. Epilepsy Behav. 2009, 14:118-20. 10.1016\/j.yebeh.2008.08.012","journal-title":"Epilepsy Behav"},{"key":"ref67","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-020-09937-7","article-title":"Seizures in Alzheimer's disease are highly recurrent and associated with a poor disease course","volume":"267","author":"V\u00f6glein J","year":"2020","unstructured":"V\u00f6glein J, Ricard I, Noachtar S, Kukull WA, Dieterich M, Levin J, Danek A. Seizures in Alzheimer's disease are highly recurrent and associated with a poor disease course. J Neurol. 2020, 267:2941-8. 10.1007\/s00415-020-09937-7","journal-title":"J Neurol"},{"key":"ref68","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2010.01.015","article-title":"Levetiracetam, lamotrigine, and phenobarbital in patients with epileptic seizures and Alzheimer's disease","volume":"17","author":"Cumbo E","year":"2010","unstructured":"Cumbo E, Ligori LD. Levetiracetam, lamotrigine, and phenobarbital in patients with epileptic seizures and Alzheimer's disease. Epilepsy Behav. 2010, 17:461-6. 10.1016\/j.yebeh.2010.01.015","journal-title":"Epilepsy Behav"},{"key":"ref69","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1331.2007.01907.x","article-title":"Levetiracetam monotherapy in Alzheimer patients with late-onset seizures: a prospective observational study","volume":"14","author":"Belcastro V","year":"2007","unstructured":"Belcastro V, Costa C, Galletti F, Pisani F, Calabresi P, Parnetti L. Levetiracetam monotherapy in Alzheimer patients with late-onset seizures: a prospective observational study. Eur J Neurol. 2007, 14:1176-8. 10.1111\/j.1468-1331.2007.01907.x","journal-title":"Eur J Neurol"},{"key":"ref70","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2021.3310","article-title":"Effect of levetiracetam on cognition in patients with Alzheimer's disease with and without epileptiform activity: a randomized clinical trial","volume":"78","author":"Vossel K","year":"2021","unstructured":"Vossel K, Ranasinghe KG, Beagle AJ, et al.. Effect of levetiracetam on cognition in patients with Alzheimer's disease with and without epileptiform activity: a randomized clinical trial. JAMA Neurol. 2021, 78:1345-54. 10.1001\/jamaneurol.2021.3310","journal-title":"JAMA Neurol"},{"key":"ref71","doi-asserted-by":"publisher","DOI":"10.1358\/dot.2007.43.11.1136902","article-title":"Levetiracetam","volume":"43","author":"Carreno M","year":"2007","unstructured":"Carreno M. Levetiracetam. Drugs Today (Barc). 2007, 43:769-94. 10.1358\/dot.2007.43.11.1136902","journal-title":"Drugs Today (Barc)"},{"key":"ref72","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2021.107939","article-title":"Behavioral adverse events with brivaracetam, levetiracetam, perampanel, and topiramate: a systematic review","volume":"118","author":"Steinhoff BJ","year":"2021","unstructured":"Steinhoff BJ, Klein P, Klitgaard H, et al.. Behavioral adverse events with brivaracetam, levetiracetam, perampanel, and topiramate: a systematic review. Epilepsy Behav. 2021, 118:107939. 10.1016\/j.yebeh.2021.107939","journal-title":"Epilepsy Behav"},{"key":"ref73","doi-asserted-by":"publisher","DOI":"10.1007\/s007020050059","article-title":"Antiglutamatergic therapy in Alzheimer's disease--effects of lamotrigine. Short communication","volume":"105","author":"Tekin S","year":"1998","unstructured":"Tekin S, Aykut-Bing\u00f6l C, Tanrida\u011f T, Aktan S. Antiglutamatergic therapy in Alzheimer's disease--effects of lamotrigine. Short communication. J Neural Transm (Vienna). 1998, 105:295-303. 10.1007\/s007020050059","journal-title":"J Neural Transm (Vienna)"},{"key":"ref74","doi-asserted-by":"publisher","DOI":"10.1212\/01.WNL.0000167384.68207.3E","article-title":"New onset geriatric epilepsy: a randomized study of gabapentin, lamotrigine, and carbamazepine","volume":"64","author":"Rowan AJ","year":"2005","unstructured":"Rowan AJ, Ramsay RE, Collins JF, et al.. New onset geriatric epilepsy: a randomized study of gabapentin, lamotrigine, and carbamazepine. Neurology. 2005, 64:1868-73. 10.1212\/01.WNL.0000167384.68207.3E","journal-title":"Neurology"},{"key":"ref75","doi-asserted-by":"publisher","DOI":"10.1007\/BF03324726","article-title":"Epileptic seizures in clinically diagnosed Alzheimer's disease: report from a geriatric medicine population","volume":"19","author":"Hommet C","year":"2007","unstructured":"Hommet C, Hureaux R, Barr\u00e9 J, Constans T, Berrut G. Epileptic seizures in clinically diagnosed Alzheimer's disease: report from a geriatric medicine population. Aging Clin Exp Res. 2007, 19:430-1. 10.1007\/BF03324726","journal-title":"Aging Clin Exp Res"},{"key":"ref76","doi-asserted-by":"publisher","DOI":"10.1001\/archgenpsychiatry.2011.72","article-title":"Chronic divalproex sodium to attenuate agitation and clinical progression of Alzheimer disease","volume":"68","author":"Tariot PN","year":"2011","unstructured":"Tariot PN, Schneider LS, Cummings J, et al.. Chronic divalproex sodium to attenuate agitation and clinical progression of Alzheimer disease. Arch Gen Psychiatry. 2011, 68:853-61. 10.1001\/archgenpsychiatry.2011.72","journal-title":"Arch Gen Psychiatry"},{"key":"ref77","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e318230a16c","article-title":"Chronic divalproex sodium use and brain atrophy in Alzheimer disease","volume":"77","author":"Fleisher AS","year":"2011","unstructured":"Fleisher AS, Truran D, Mai JT, et al.. Chronic divalproex sodium use and brain atrophy in Alzheimer disease. Neurology. 2011, 77:1263-71. 10.1212\/WNL.0b013e318230a16c","journal-title":"Neurology"},{"key":"ref78","doi-asserted-by":"publisher","DOI":"10.1007\/pl00005060","article-title":"Phenytoin's effect on the spread of seizure activity in the amygdala kindling model","volume":"356","author":"Ebert U","year":"1997","unstructured":"Ebert U, Cramer S, L\u00f6scher W. Phenytoin's effect on the spread of seizure activity in the amygdala kindling model. Naunyn Schmiedebergs Arch Pharmacol. 1997, 356:341-7. 10.1007\/pl00005060","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"ref79","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-199309020-00003","article-title":"Benzodiazepine dependence. Avoidance and withdrawal","volume":"9","author":"Marriott S","year":"1993","unstructured":"Marriott S, Tyrer P. Benzodiazepine dependence. Avoidance and withdrawal. Drug Saf. 1993, 9:93-103. 10.2165\/00002018-199309020-00003","journal-title":"Drug Saf"},{"key":"ref80","doi-asserted-by":"publisher","DOI":"10.2146\/ajhp160381","article-title":"Benzodiazepine use and cognitive decline in the elderly","volume":"75","author":"Picton JD","year":"2018","unstructured":"Picton JD, Marino AB, Nealy KL. Benzodiazepine use and cognitive decline in the elderly. Am J Health Syst Pharm. 2018, 75:e6-e12. 10.2146\/ajhp160381","journal-title":"Am J Health Syst Pharm"},{"key":"ref81","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.g5205","article-title":"Benzodiazepine use and risk of Alzheimer's disease: case-control study","volume":"349","author":"Billioti de Gage S","year":"2014","unstructured":"Billioti de Gage S, Moride Y, Ducruet T, et al.. Benzodiazepine use and risk of Alzheimer's disease: case-control study. BMJ. 2014, 349:g5205. 10.1136\/bmj.g5205","journal-title":"BMJ"},{"key":"ref82","doi-asserted-by":"publisher","DOI":"10.3390\/cells9112517","article-title":"Human pluripotent stem cells-based therapies for neurodegenerative diseases: current status and challenges","volume":"9","author":"Ford E","year":"2020","unstructured":"Ford E, Pearlman J, Ruan T, Manion J, Waller M, Neely GG, Caron L. Human pluripotent stem cells-based therapies for neurodegenerative diseases: current status and challenges. Cells. 2020, 9:10.3390\/cells9112517","journal-title":"Cells"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/111336-the-association-between-alzheimers-disease-and-epilepsy-a-narrative-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:49:32Z","timestamp":1707508172000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/111336-the-association-between-alzheimers-disease-and-epilepsy-a-narrative-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,11]]},"references-count":82,"URL":"https:\/\/doi.org\/10.7759\/cureus.30195","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10,11]]}}}